infliximab
Last reviewed 01/2018
Infliximab is a chimeric humanised mouse anti-TNF monoclonal antibody, that binds to and inhibits human TNF-alpha.
It has been used in the treatment for acute Crohn's disease, but was primarily designed for the treatment of rheumatoid arthritis.
It is given by intravenous infusion at 0,2 and 6 weeks then every 8 weeks thereafter. It is licensed for concomitant use with Methotrexate in adults with RA responding inadequately to DMARDs including methotrexate.
Check the Summary of Product Characteristics before prescribing this drug.
contraindications to the use of infliximab
clinical efficacy of infliximab
infliximab in Crohn's disease and ulcerative (UC) colitis
NICE guidance - the use of infliximab or adalimumab in Crohn's disease
anti-TNF alpha therapies for rheumatoid arthritis
NICE guidance - infliximab for the treatment for adults with psoriasis